Patterns of, and factors associated with, atypical and typical antipsychotic prescribing by general practitioners in the UK during the 1990s

References

• Almond S., Knapp M., Francois C., Toumi M., Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. British Journal of Psychiatry 2004; 184: 346–351
   PubMed Web of Science ®Google Scholar
• Ashcroft D., Frischer M., Lockett J., Chapman S. Variations in prescribing atypical antipsychotic drugs in primary care: Cross-sectional study. Pharmacoepidemiology and Drug Safety 2002; 11: 285–289
   PubMed Web of Science ®Google Scholar
• Basu A. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: Critical review of results and methodological issues. Schizophrenia Research 2004; 71: 445–462
   PubMed Web of Science ®Google Scholar
• Bebbington P. Choosing antipsychotic drugs in schizophrenia. Psychiatric Bulletin 2001; 25: 284–286
   Google Scholar
• Bushe C., Leonard B. Association between atypical antipsychotic agents and type 2 diabetes: A review of prospective clinical data. British Journal of Psychiatry 2004; 184(Suppl. 47)S87–S93
   Google Scholar
• Davis J., Chen N., Glick I. A meta-analysis of the efficacy of second-generation anti-psychotics. Archives of General Psychiatry 2003; 60: 553–564
   PubMed Web of Science ®Google Scholar
• Duggan M. Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. Journal of Health Economics 2005; 24: 1–31
   PubMed Web of Science ®Google Scholar
• Gill S. S., Rochon P. A., Hermann N., Lee P. E., Sykora K., Gunraj N., Normane S. L. T., Gurwitz J. H., Marras C., Wodchis W. P., Mamdani M. Atypical antipsychotic drugs and risk of ischaemic stroke: Population based retrospective cohort study. British Medical Journal 2005; 330: 445–448
   PubMed Web of Science ®Google Scholar
• Hayhurst K., Brown P., Lewis S. Postcode prescribing for schizophrenia. British Journal of Psychiatry 2003; 182: 281–283
   PubMed Web of Science ®Google Scholar
• Hogman G. Is cost a factor? A survey of psychiatrists and health authorities to determine the factors influencing the prescribing and funding of atypical antipsychotics. National Schizophrenia Fellowship, London 1996
   Google Scholar
• Hudson T. J., Sullivan G., Feng W., Owen R. R., Thrush C. R. Economic evaluations of novel antipsychotic medications: A literature review. Schizophrenia Research 2003; 60: 199–218
   PubMed Web of Science ®Google Scholar
• IMS Health. Sales evolution of atypical antipsychotics 1991 – 2002 in Local Currency Dollars. IMS Health Incorporated, FairfieldUSA 2003
   Google Scholar
• Kaye J., Bradbury B., Jick H. Changes in antipsychotic drug prescribing by general practitioners in the UK from 1991 to 2000: A population-based observational study. British Journal of Clinical Pharmacology 2003; 56: 569–575
   PubMed Web of Science ®Google Scholar
• Leucht S., Pitschel-Walz G., Abraham D., Kissing W. Efficacy and extrapryamidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomised controlled trials. Schizophrenia Research 1999; 35: 51–68
   PubMed Web of Science ®Google Scholar
• Mortimer A. M. Antipsychotic treatment in schizophrenia: Atypical options and NICE guidance. European Psychiatry 2003; 18: 209–219
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence (NICE). Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. NHS. 2002, Technology Appraisal Guidance No. 43
   Google Scholar
• Northern and Yorkshire Regional Drug and Therapeutics Centre. The use of atypical antipsychotics in the management of schizophrenia. 1998, Accessed on-line on 23 January 2006 at: http://www.nyrdtc.nhs.uk/docs/eva/atypical_antipsychotics.pdf
   Google Scholar
• Opolka J. L., Rascati K. L., Brown C. M., Gibson P. J. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatric Services 2004; 55: 151–156
   PubMed Web of Science ®Google Scholar
• Patel M. X., Nikolaou V., David A. S. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychological Medicine 2003; 33: 83–89
   PubMed Web of Science ®Google Scholar
• Paton C., Lelliott P., Harrington M., Okocha C., Sensky T., Duffett R. Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. Journal of Psychopharmacology 2003; 17: 223–229
   PubMed Web of Science ®Google Scholar
• Percudani M., Barbui C., Fortino I., Tansella M., Petrovich L. Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. Journal of Clinical Psychopharmacology 2005; 25: 468–470
   PubMed Web of Science ®Google Scholar
• Rethink (formerly known as the National Schizophrenia Fellowship). That's Just Typical, http://www.rethink.org/publications/pdfs/Typical-report.pdf(Accessed 3 March 2005)
   Google Scholar
• Rogers A., Campbell S., Gask L., Sheaff R., Marshall M., Halliwell S., Pickard S. Some National Service Frameworks are more equal than others: Implementing clinical governance for mental health in primary care groups and trusts. Journal of Mental Health 2002; 11: 199–212
   Google Scholar
• Sartorius N., Fleischhacker W., Gjerris A., Kern U., Knapp M., Leonard B., Lieberman J., Lopez-Ibor J. J., van Raay B., Twomey E. The usefulness of and use of second-generation antipsychotic medications: Review of evidence and recommendations by a Task Force of the World Psychiatric Association. Current Opinion in Psychiatry 2002; 15(Suppl. 1)S1–S51
   Google Scholar
• Sartorius N., Fleischhacker W., Gjerris A., Kern U., Knapp M., Leonard B., Lieberman J., Lopez-Ibor J. J., van Raay B., Twomey E. The usefulness of and use of second-generation antipsychotic medications: An update. Current Opinion in Psychiatry 2003; 16(Suppl. 1)S1–S44
   Google Scholar
• Stark C., Jones J., Agnew J., Hepburn T. Antipsychotic drug prescribing trends in primary care in Scotland 1994-97. Health Bulletin (Edinburgh) 2000; 58: 96–101
   PubMedGoogle Scholar
• STATA. STATA. Stata Corporation, College Station, TX 2001
   Google Scholar
• Taylor D., Mace S., Mir S., Kerwin R. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the UK. International Journal of Psychiatry in Clinical Practice 2000; 4: 41–46
   PubMed Web of Science ®Google Scholar
• Walley T. Neuropsychotherapeutics in the UK: What has been the impact of NICE on prescribing?. CNS Drugs 2004; 18: 1–12
   PubMed Web of Science ®Google Scholar
• Walley T., Mantgani A. The UK General Practice Research Database. The Lancet 1997; 350: 1097–1099
   PubMed Web of Science ®Google Scholar
• Weiden P. J., Olfson M. Cost of relapse in schizophrenia. Schizophrenia Bulletin 1995; 21: 419–429
   PubMed Web of Science ®Google Scholar
• Wood L., Coulson R. Revitalizing the General Practice Research Database: Plans, challenges, and opportunities. Pharmacoepidemiology and Drug Safety 2001; 10: 379–383
   PubMed Web of Science ®Google Scholar
• Wooltorton E. Risperidone (Risperdal): Increased rate of cerebrovascular events in dementia trials. Canadian Medical Association Journal 2002; 167: 1269–1270
   PubMed Web of Science ®Google Scholar
• Valenti A. M., Narendram R., Pristach C. A. Who are patients on conventional antipsychotics?. Schizophrenia Bulletin 2003; 29: 195–199
   PubMed Web of Science ®Google Scholar